CompletedNot Applicable

Clinical Analysis of Juvenile Dermatomyositis Patients

12 participantsStarted 2014-01-01

Plain-language summary

This study aimed to investigate the clinical effectivity of intravenous methylprednisolone repeated intermittent pulse combined with mycophenolate mofetil in the treatment of newly diagnosed juvenile dermatomyositis.

Who can participate

Age range16 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. patients with age of JDM onset \<16 years
✓. newly treated cases
✓. no contraindications to corticosteroids
✓. provide signed informed consent form
✓. regular follow-up for more than 30 months.

Exclusion criteria

✕. patients with serious complications of heart, liver and kidney
✕. patients with a history of contraindications and/or allergies to GC
✕. patients who underwent treatment before admission
✕. patients who failed to regularly follow-up
✕. patients with positive anti-melanoma differentiation-associated gene 5 (MDA5) antibodies

What they're measuring

Change from baseline in CMAS score

Timeframe: 1, 3, 6, 12, 18, 24 and 36 months

Trial details

NCT IDNCT05509140

SponsorThe First Hospital of Jilin University

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2020-12-31

View on ClinicalTrials.gov More Juvenile Dermatomyositis trials